GRTX: רווח למניה בשנים עשר החודשים האחרונים galeratx.com

Galera Therapeutics (GRTX) capital burned through in laboratories, creating negative leverage. The current trailing 12-month EPS on GURU.Markets confirms this trend, where the -0.92 figure reflects the metric's balance. Despite past partnerships regarding tissue protection during irradiation, all scientific research has now ceased, and the company's biotechnological business and assets have been fully liquidated.
Galera (GRTX) - פילוחי מדדים ודוחות פיננסיים

Galera Therapeutics (GRTX) represents a classic example of a high-risk biotech startup. By analyzing the annual net income per share trend, an investor sees the final financial result distributed across the entire volume of the issuance. This metric objectifies the real value of the business, separating market expectations from actual profitability. The negative trend confirms a total lack of profit following the closure of key programs. The company's fundamental value is trending toward zero due to the winding down of operational activities.